Swipe Left For English News
上海,
2023年10月31日
全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）宣布公司荣获《财资》2023年度ESG企业大奖铂金奖。公司连续三年获此殊荣，充分证明投资市场对公司环境、社会和公司治理（ESG）战略的认可，亦是对公司致力于可持续发展之路的肯定。
作为国际权威财经新闻及商业研究机构，《财资》重点关注企业的ESG以及可持续性表现。“《财资》ESG企业大奖”每年对候选企业的多个指标进行评估，包括能源消耗和温室气体排放、废弃物和水资源管理、供应商行为准则、可持续性融资和公司治理等。药明生物也是生物药CRDMO领域唯一获此殊荣的公司。
陈智胜
博士
药明生物首席执行官
ESG委员会主席
我们很高兴再度获得《财资》颁发的铂金奖，这是对我们在行业内ESG先锋地位的高度认可。过去一年，药明生物在ESG方面的坚定承诺和积极实践得到了国际评级机构的广泛肯定。非常感谢全球合作伙伴、投资者和社会公众对我们的信赖，我们将继续践行ESG战略，并巩固其作为公司护城河之一的地位，更好地赋能全球合作伙伴，造福广大病患。
药明生物始终将可持续发展视为企业发展战略的基石。2023年，公司在气候变化、多元化、平等与包容（DEI）、负责任治理和可持续采购等ESG重大议题上取得了显著成果。5月，公司成立了推动完善DEI管理体系的最高管理组织——DEI委员会；6月，公司宣布签署科学碳目标倡议（SBTi）承诺书，稳步迈向净零排放的新里程碑。此外，药明生物还于9月加入联合国全球契约组织 (UNGC)，通过合作与伙伴关系共同推进更广泛的联合国目标，以履行其对企业和社会可持续发展的承诺。
推荐阅读
关于药明生物
药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）服务公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物人的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2023年6月底，药明生物帮助客户研发和生产的综合项目高达621个，其中包括22个商业化生产项目。
药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的重要组成部分，并致力于成为全球生物药CRDMO领域的ESG领导者，例如应用更绿色环保的新一代生物制药技术和能源等引领行业发展。公司成立了由首席执行官领导的ESG委员会，全面落实ESG战略并践行可持续性发展承诺。
更多信息，请访问：www.wuxibiologics.com
ESG
esg@wuxibiologics.com
媒体关系
PR@wuxibiologics.com
WuXi Biologics Receives The Asset ESG Corporate Platinum Award for Third Consecutive Year
Shanghai,
October 31, 2023
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has received a Platinum Award from The Asset ESG Corporate Awards for the third year in a row. The honor recognizes the company's adherence to ESG principles and is a reflection of its deep commitment to sustainability.
The Asset, a widely recognized business news and research organization, evaluates companies regarding their ESG responsibilities for its annual ESG Corporate Awards, reviewing a wide range of metrics, including energy consumption and GHG emissions, waste and water management, supplier codes of conduct, sustainability financing, and corporate governance. WuXi Biologics is the only biologics CRDMO company among the winners.
Dr. Chris Chen
Chief Executive Officer
Chairman of the ESG Committee
WuXi Biologics
We are very pleased to receive a Platinum Award from The Asset for the third time, a demonstration of WuXi Biologics' industry-leading ESG performance. Our ESG commitments and efforts were widely recognized by multiple rating agencies and index providers during the past year. We appreciate the trust and support of our global partners, investors and local communities, and will continue to enhance our ESG capabilities – through comprehensive strategy and refined initiatives – for a sustainable future and for the benefit of patients worldwide.
WuXi Biologics regards sustainability as the cornerstone of its business development strategy. In 2023, notable progress was made particularly on the ESG material issues of climate change; diversity, equity, and inclusion (DEI); responsible governance; and sustainable procurement. This May, the company established a DEI Committee as the highest-level management body to oversee and further advance DEI efforts. In June, it announced the signing of the Science Based Targets initiative (SBTi) commitment letter, marking a new milestone in the company's net-zero efforts. Additionally, in September, WuXi Biologics became a signatory of the United Nations Global Compact (UNGC), which demonstrates its commitment to sustainable and socially responsible policies.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2023, WuXi Biologics is supporting 621 integrated client projects, including 22 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
Contacts
ESG
esg@wuxibiologics.com
Media
PR@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
